Open Book Extracts (OBX), a manufacturer and distributor of cannabinoid ingredients and finished products, today announced the completion of its first randomised, controlled trial on rare cannabinoids, with the support of Radicle Science.
Radicle Science conducted a study on several OBX formulations. The study was a four-week blinded, randomised, controlled, parallel group comparison of the effects of various cannabinoid formulations on longer-term pain, well-being, and quality of life.
"We are excited to have partnered with OBX to conduct history's largest randomised, controlled trial of cannabinoids for pain, involving nearly 2,000 participants from across the U.S. This groundbreaking study also represents history's first randomised controlled trial on the synergistic impact of rare cannabinoids like CBC and CBG on pain,” said Dr Jeff Chen, MD/MBA, co-founder, and CEO of Southern California-based Radicle Science.
“A majority of all phytocannabinoid clinical research has centered around THC, and we are uncovering the untapped potential in the other phytocannabinoids found in the cannabis and hemp plant."
Results from the pain study are expected in late April 2022 and will be announced at that time.
In addition, OBX and Radicle Science will launch the first large-scale, blinded, randomised, placebo-controlled clinical trials on rare cannabinoids including THCV, CBN, CBG, and CBC, to study their effects on energy, focus, appetite, sleep disturbance, stress, and anxiety across more than 10,000 study participants.
“Validating the therapeutic benefits of cannabinoids with scientifically-backed research is a source of great pride for our company,” said Dave Neundorfer, chief executive officer, for Roxboro, NC-based OBX. “We are on a quest to understand the true potential of cannabinoids and thank the Radicle Science team for providing a platform that supports the research that will help transform the CBD industry. The completion of this study is a key milestone in our research efforts and further demonstrates our commitment to scientific research and development for the cannabinoid industry as a whole.”
